Cycle Design: On/Off Timing, Washout Periods, and Stack Rotation

Why Cycling Matters

The case for cycling peptide protocols rests on four distinct reasons, and understanding each one separately helps clarify why different compounds have different cycle requirements.

First: receptor downregulation. When a receptor is continuously stimulated, the cell adapts by reducing receptor density on the surface. This is a universal biological response to sustained agonist presence. For GH secretagogues acting on the GHS-R1a receptor, continuous administration without breaks risks progressively blunting the GH response over time. Washout periods allow receptor density to normalize.

Second: axis suppression risk. GH secretagogue protocols augment the GH axis. Extended continuous augmentation raises theoretical questions about whether endogenous GH output atrophies when the exogenous stimulus does all the work. Cycling preserves the axis's capacity for independent function during off-periods.

Third: cost management. Responsible protocol design acknowledges that sustainability matters. A protocol that is too expensive to maintain long-term is not a protocol; it is a temporary experiment. Cycling with off-periods reduces cost while preserving outcome quality.

Fourth: data quality. A continuous protocol with no washout periods blends effects across time, making it impossible to identify which compounds are contributing, whether adaptation is occurring, or whether baseline function has changed. Washout periods create clean measurement windows.

The General Cycle Framework

The 8-weeks-on, 4-weeks-off framework is the starting point for most peptide cycles in this curriculum. This 12-week total cycle length aligns conveniently with quarterly planning. Four quarters of 12 weeks each create a natural annual rhythm. The 8-week active phase provides sufficient time for biological effects to manifest and for lab markers to reflect the protocol's impact. The 4-week washout provides time for receptor resensitization and for establishing a clean baseline measurement.

  Q1 (Weeks 1-12)
    Weeks 1-8:   Active Phase - Healing focus (BPC-157 + TB-500 + GHK-Cu + Ipamorelin)
    Weeks 9-12:  Washout - baseline labs at week 10
    |
  Q2 (Weeks 13-24)
    Weeks 13-20: Active Phase - Performance focus (GH secretagogue full stack)
    Weeks 21-24: Washout - peak-marker labs at week 20, baseline recheck at 24
    |
  Q3 (Weeks 25-36)
    Weeks 25-32: Active Phase - Cognitive/Recovery focus (Semax + Selank + healing maintenance)
    Weeks 33-36: Washout - cognitive markers, lab panel
    |
  Q4 (Weeks 37-48)
    Weeks 37-44: Active Phase - Metabolic assessment (evaluate GLP-1 class candidacy)
    Weeks 45-48: Annual assessment - full panel, planning next year
      

Compound-Specific Cycle Lengths

The 8 on/4 off framework is a useful starting default, but individual compounds have different cycling requirements based on their mechanism.

Washout Periods Defined

A washout period serves two functions: clearance and resensitization. Clearance is the time for compound concentration to fall to negligible levels. For most short-half-life peptides, this occurs within days. The resensitization component takes longer: receptor density recovers, axis dynamics normalize, and the baseline physiological state is restored. This is why 4 weeks is used rather than just allowing one pharmacokinetic half-life to pass. You are not just clearing the compound; you are resetting the biological context.

Lab draws scheduled during the washout period should be timed to capture both the peak-effect markers (drawn at or near the end of the active phase before stopping) and the baseline recovery markers (drawn at the mid-to-late washout to confirm the axis is returning to its pre-protocol state). If the washout-period baseline does not return toward pre-protocol values, this is a signal that the protocol has produced persistent axis modification, which requires assessment.

Maintenance vs. Loading Protocols

The loading versus maintenance distinction applies primarily to compounds with long distribution times (TB-500) or where the initial dose needs to build tissue levels before effect is seen. Loading protocols use higher frequency or higher dose for an initial window, then step down to a lower maintenance frequency once the target tissue level is established. For BPC-157, loading might mean twice-daily dosing for the first 2-4 weeks, stepping down to once daily for the remainder. For TB-500, weekly injections for 4-6 weeks, then monthly. Understanding this distinction prevents the common error of abandoning a compound during the loading phase before tissue levels are adequate to produce observable effects.

The Stack Rotation Concept

Stack rotation means shifting the primary compound focus each quarter to address different optimization objectives systematically. Rather than running all compounds simultaneously at all times (which produces high cost, complex data, and potential interaction effects), rotation concentrates resources and measurement attention on one primary objective per quarter. The four-quarter rotation that maps to this curriculum is: Q1 healing and repair foundation, Q2 performance and GH optimization, Q3 cognitive enhancement and recovery consolidation, Q4 metabolic assessment and annual planning.

Lab Timing Across the Cycle

Lab draws should be strategically timed to capture both the maximum effect of the protocol and the pre-protocol baseline. A draw at the end of week 8 (final week of active phase) captures peak IGF-1, peak repair markers, and any other compound-specific markers at their highest protocol-driven level. A draw at week 10-11 (mid-washout) captures the transition back toward baseline. A draw at week 12 (end of washout, start of next quarter) serves as the pre-protocol baseline for the next active phase. Four draws per year, two per cycle, provides sufficient longitudinal data to track trends across an annual program.